{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MM-II+dose+II&page=2",
    "query": {
      "intervention": "MM-II dose II",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MM-II+dose+II&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T06:09:53.240Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00179907",
      "title": "A Phase I/II Study of the Photon Radiosurgery System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor, Recurrent",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Photon Radiosurgery System (Intrabeam)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "32 Years",
        "sex": "ALL",
        "summary": "2 Years to 32 Years"
      },
      "enrollment_count": 35,
      "start_date": "2001-05",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-02",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179907"
    },
    {
      "nct_id": "NCT00347555",
      "title": "Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Malaria"
      ],
      "interventions": [
        {
          "name": "Aluminum Phosphate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EBA-175 RII-NG Malaria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 80,
      "start_date": "2006-05",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2013-04-12",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347555"
    },
    {
      "nct_id": "NCT02394665",
      "title": "Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Intensity Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Functional Assessment of Cancer Therapy-Brain (FACT-Br)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stereotactic Radiosurgery Boost",
          "type": "RADIATION"
        },
        {
          "name": "Simultaneous Integrated Boost",
          "type": "RADIATION"
        },
        {
          "name": "3D MRSI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-03",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-05",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02394665"
    },
    {
      "nct_id": "NCT00849147",
      "title": "Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",
        "Leukemia, Myeloid, Acute",
        "Burkitt Lymphoma",
        "Lymphoma, B-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Haploidentical Bone Marrow Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GVHD prophylaxis",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "1 Year to 70 Years"
      },
      "enrollment_count": 55,
      "start_date": "2008-10",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 17,
      "location_summary": "Duarte, California • La Jolla, California • Gainesville, Florida + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849147"
    },
    {
      "nct_id": "NCT01862250",
      "title": "Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Encephalopathy, Hypoxic-Ischemic"
      ],
      "interventions": [
        {
          "name": "Clonidine (Duraclon®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Weeks",
        "maximum_age": "42 Weeks",
        "sex": "ALL",
        "summary": "35 Weeks to 42 Weeks"
      },
      "enrollment_count": 13,
      "start_date": "2013-10-03",
      "completion_date": "2015-04-14",
      "has_results": true,
      "last_update_posted_date": "2018-01-05",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862250"
    },
    {
      "nct_id": "NCT04094961",
      "title": "Ixazomib + Pomalidomide + Dexamethasone In MM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omar Nadeem, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2019-09-18",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04094961"
    },
    {
      "nct_id": "NCT04987996",
      "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "GR-MD-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-07-01",
      "completion_date": "2031-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987996"
    },
    {
      "nct_id": "NCT04506463",
      "title": "Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of Knee"
      ],
      "interventions": [
        {
          "name": "MM-II dose I",
          "type": "DRUG"
        },
        {
          "name": "MM-II dose II",
          "type": "DRUG"
        },
        {
          "name": "MM-II dose III",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "40 Years to 99 Years"
      },
      "enrollment_count": 397,
      "start_date": "2020-12-22",
      "completion_date": "2022-08-10",
      "has_results": true,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Tempe, Arizona • Riverside, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04506463"
    },
    {
      "nct_id": "NCT00648739",
      "title": "Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Chronic Lymphocytic Leukemia",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Samalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 26,
      "start_date": "2008-06-19",
      "completion_date": "2010-12-14",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • Atlanta, Georgia • Morristown, New Jersey + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648739"
    },
    {
      "nct_id": "NCT01695330",
      "title": "Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Subcutaneous bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-05",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-16",
      "last_synced_at": "2026-09-27T06:09:53.240Z",
      "location_count": 1,
      "location_summary": "West Hollywood, California",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01695330"
    }
  ]
}